Foresite Capital Management IV, LLC
Long book
$237.1M
Q1 2026
Positions
8
Top-10 weight
100%
concentration
Last quarter
+19.1%
SPY +14.8%
Turnover
13%
of book per quarter
Strategy in plain words
auto-generated from filingsForesite Capital Management IV, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $237.1M US long book across 8 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: PHARVARIS NV, CYTOKINETICS INC, EIKON THERAPEUTICS INC, LYELL IMMUNOPHARMA INC, RELAY THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 0.7pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-16.3%
Q2 2024
-3.3%
Q3 2024
-20.6%
Q4 2024
-19.5%
Q1 2025
+8.5%
Q2 2025
+58.9%
Q3 2025
+22.5%
Q4 2025
-2.3%
Q1 2026
+19.1%
Sector allocation
Healthcare 100%
Long book by quarter
What does Foresite Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PHVS PHARVARIS NV | Healthcare | 4.8M | $135.0M | 56.9% | Held |
| CYTK CYTOKINETICS INC | Healthcare | 503.3K | $33.2M | 14.0% | +9.8% |
| EIKN EIKON THERAPEUTICS INC | Healthcare | 1.9M | $20.6M | 8.7% | New |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 800.4K | $16.1M | 6.8% | Held |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 1.0M | $9.9M | 4.2% | Held |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 160.0K | $9.3M | 3.9% | Held |
| ALEC ALECTOR INC | Healthcare | 3.9M | $8.4M | 3.5% | Held |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 156.9K | $4.7M | 2.0% | -70.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 8 | $237.1M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 7 | $229.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 6 | $182.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 12, 2025 | 6 | $123.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 5 | $111.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 4 | $108.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 5 | $153.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 4 | $148.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 5 | $197.9M | canonical | SEC ↗ |